גורמי סיכון לתמותה בחולי שבץ הזקוקים להנשמה מכנית

מן הרשת

עמוד 7 מתוך 56
<
1
...
2
3
4
5
6
7
8
9
10
11
...
56
>

06.03.2025

12:37

Early Disease-Modifying Treatments for Presymptomatic Multiple Sclerosis

Discussing each RIS case with an expert MS team is recommended because there is still a lack of clinical guidelines to improve care, counseling, and surveillance

CNS Drugs

06.03.2025

12:36

Management of multiple sclerosis in older adults

review of current evidence and future perspectives

Journal of Neurology

05.03.2025

13:59

Sex Differences in Longitudinal Tau-PET in Preclinical Alzheimer Disease

Is sex associated with rate of regional tau accumulation in adults without cognitive impairment at baseline?

JAMA Neurology

26.01.2025

11:04

הבדלי מין ומגדר בחשיפה לאלימות במהלך הילדות והשפעתה בבגרות על תחלואה גופנית כרונית

התעללות בילדים (אילוסטרציה)

לאלימות ולהתעללות כלפי ילדים יש השפעה ארוכת טווח על בריאות הגוף והנפש. בעוד שהקשר לבריאות הנפש אינטואיטיבי למדי, בשנים האחרונות מתחוור הקשר שבין פגיעה בגיל ילדות לבין עלייה בתחלואה גופנית כרונית בבגרות. בסקירה זו ביקשנו להביט על קשר זה דרך עדשה מגדרית

לנה אבייב, ענבל מנדלר, ליאור ברוך, הרפואה

22.01.2025

12:42

Datopotamab Deruxtecan in Advanced or Metastatic NSCLC With Actionable Genomic Alterations

Results From the Phase II TROPION-Lung05 Study

Journal of Clinical Oncology

22.01.2025

12:40

Tyrosine Kinase Inhibitors for Brain Metastases

Tyrosine Kinase Inhibitors With and Without Up-Front Stereotactic Radiosurgery for Brain Metastases From EGFR and ALK Oncogene–Driven Non–Small Cell Lung Cancer (TURBO-NSCLC)

Journal of Clinical Oncology

22.01.2025

12:39

Subcutaneous Versus Intravenous Amivantamab

Subcutaneous Versus Intravenous Amivantamab, Both in Combination With Lazertinib, in Refractory Epidermal Growth Factor Receptor–Mutated Non–Small Cell Lung Cancer: Primary Results From the Phase III PALOMA-3 Study

Journal of Clinical Oncology

22.01.2025

12:38

Pemetrexed and Platinum for NSCLC

Phase III KEYNOTE-789 Study of Pemetrexed and Platinum With or Without Pembrolizumab for Tyrosine Kinase Inhibitor‒Resistant, EGFR–Mutant, Metastatic Nonsquamous Non–Small Cell Lung Cancer

Journal of Clinical Oncology

22.01.2025

12:36

Therapy for Stage IV Non–Small Cell Lung Cancer With Driver Alterations

ASCO Living Guideline, Version 2024.2

Journal of Clinical Oncology

22.01.2025

12:35

TERT Expression and Clinical Outcome in Pulmonary Carcinoids

We investigated whether TERT expression defines the clinical fate of patients with pulmonary carcinoid

Journal of Clinical Oncology

22.01.2025

12:34

Systemic Therapy for Small Cell Lung Cancer

ASCO Guideline Rapid Recommendation Update

Journal of Clinical Oncology

22.01.2025

12:33

Body Weight Gain Associated With Alectinib in Patients With ALK+ NSCLC

Pooled Analysis of Individual Patient Data From Four Prospective Clinical Trials

Journal of Clinical Oncology

22.01.2025

12:31

Treatment of Pleural Mesothelioma: ASCO Guideline Update

ASCO Guidelines provide recommendations with comprehensive review and analyses of the relevant literature for each recommendation, following the guidelines development process as outlined in the ASCO Guidelines Methodology Manual.

Journal of Clinical Oncology

22.01.2025

12:30

Neoadjuvant Nivolumab Plus Ipilimumab Versus Chemotherapy in Resectable Lung Cancer

We report results from the exploratory concurrently randomized nivolumab plus ipilimumab and chemotherapy arms of the international phase III CheckMate 816 trial

Journal of Clinical Oncology

05.01.2025

12:20

SUO 2024: Adjuvant Systemic Therapy in Urothelial Carcinoma: Where Are We At Today?

The 2024 Society of Urologic Oncology (SUO) annual meeting held in Dallas, TX was host to an Advanced Disease and Adjuvant Therapy session. Dr. Jean Hoffman-Censits discussed the current state of adjuvant systemic therapy for urothelial carcinoma

Uro Today

עמוד 7 מתוך 56
<
1
...
2
3
4
5
6
7
8
9
10
11
...
56
>